2014•Central Plains Medical JournalRequires access

Clinical analysis of MEA and HEA regimen in treatment of adult refractory acute monocytic leukemia

Rui Liu, Zhongxing Jiang, Fang Wang, Wei-qiong Wang

Open publisher page 0 citations

Abstract

Objective To compare the clinical efficiency and security of MEA (Mitoxantrone,Cytarabine,Etoposide)and HEA (Homoharringtonine,Cytarabine,Etoposide) protocols on acute monouclear leukemia.Methods Forty-six replapsed or refractory patients were enrolled in this study.Twentysix patients were administered with MEA and 20 patients were administered with HEA,and then the clinical curative effect and side effects of the two groups were observed.Results Clinical response of MEA regimen:17 out of 26 patients (65.4%) achieved complete remission (CR),5 cases (19.2%) achieved partial remission(PR),4 cases(15.4%) no response.Clinical response of HEA regimen:9 out of 20 patients(45%) achieved CR,5cases(19.2%) achieved PR,4 cases(15.4%) no response.Conclusions MEA solutions is more effective than HEA solutions,MEA regimen can be used as a recurrent or refractory acute mononuclear leukemia chemotherapy regimens of priority. Key words: Acute monouclear leukemia;  Mitoxantrone ;  Homoharringtonine ;  Etoposide

About this research paper

What this paper is about

Objective To compare the clinical efficiency and security of MEA (Mitoxantrone,Cytarabine,Etoposide)and HEA (Homoharringtonine,Cytarabine,Etoposide) protocols on acute monouclear leukemia.Methods Forty-six replapsed or refractory patients were enrolled in this study.Twentysix patients were administered with MEA and 20 patients were administered with HEA,and then the clinical curative effect and side effects of the two groups were observed.Results Clinical response of MEA regimen:17 out of 26 patients (65.4%) achieved complete remission (CR),5 cases (19.2%) achieved partial remission(PR),4 cases(15.4%) no response.Clinical response of HEA regimen:9 out of 20 patients(45%) achieved CR,5cases(19.2%) achieved PR,4 cases(15.4%) no response.Conclusions MEA solutions is more effective than HEA solutions,MEA regimen can be used as a recurrent or refractory acute mononuclear leukemia chemotherapy regimens of priority. Key words: Acute monouclear leukemia;  Mitoxantrone ;  Homoharringtonine ;  Etoposide

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective To compare the clinical efficiency and security of MEA (Mitoxantrone,Cytarabine,Etoposide)and HEA (Homoharringtonine,Cytarabine,Etoposide) protocols on acute monouclear leukemia.Methods Forty-six replapsed or refractory patients were enrolled in this study.Twentysix patients were administered with MEA and 20 patients were administered with HEA,and then the clinical curative effect and side effects of the two groups were observed.Results Clinical response of MEA regimen:17 out of 26 patients (65.4%) achieved complete remission (CR),5 cases (19.2%) achieved partial remission(PR),4 cases(15.4%) no response.Clinical response of HEA regimen:9 out of 20 patients(45%) achieved CR,5cases(19.2%) achieved PR,4 cases(15.4%) no response.Conclusions MEA solutions is more effective than HEA solutions,MEA regimen can be used as a recurrent or refractory acute mononuclear leukemia chemotherapy regimens of priority. Key words: Acute monouclear leukemia;  Mitoxantrone ;  Homoharringtonine ;  Etoposide

Key concepts: Etoposide, Homoharringtonine, Mitoxantrone, Medicine, Regimen, Cytarabine, Refractory (planetary science), Internal medicine

Related papers

Back to paper searchBrowse research topicsOriginal source
Clinical analysis of MEA and HEA regimen in treatment of adult refractory acute monocytic leukemia — Research Paper | ScholarLens